search
Back to results

Synbiotics in Patients at RIsk fOr Preterm Birth (PRIORI)

Primary Purpose

Preterm Spontaneous Labor With Preterm Delivery, Preterm Birth, Microbial Colonization

Status
Recruiting
Phase
Not Applicable
Locations
Belgium
Study Type
Interventional
Intervention
Synbiotics
Placebo
Sponsored by
Ziekenhuis Oost-Limburg
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional other trial for Preterm Spontaneous Labor With Preterm Delivery focused on measuring Preterm birth, Vaginal microbiome, Probiotics, Synbiotics

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)FemaleAccepts Healthy Volunteers

Inclusion Criteria: Signed written informed consent must be obtained before any study assessment is performed; 18 years of age or older; Singleton pregnancy; Pregnancy consultation between 8 and 10 weeks gestation. At least one of the following risk factors for spontaneous preterm birth: Prior spontaneous preterm birth, defined as delivery between 24 and 37 weeks following PPROM, preterm labor or cervical insufficiency PPROM ≤37 weeks in previous pregnancy but delivery ≥37 weeks Prior spontaneous second-trimester pregnancy loss, defined as PPROM, preterm labor or cervical insufficiency with birth between 14 and 24 weeks. Exclusion Criteria: Patients who are already using pro-, pre- or synbiotics Multiple pregnancy Need for primary (type 1) cerclage Inflammatory bowel disease Known congenital uterine anomaly History of LLETZ conization

Sites / Locations

  • Ziekenhuis Oost-LimburgRecruiting
  • Universitaire Ziekenhuizen Leuven
  • UZ GentRecruiting
  • AZ Sint-JanRecruiting
  • AZ Sint-LucasRecruiting
  • CHR CitadelleRecruiting

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Placebo Comparator

Arm Label

Synbiotics

Placebo

Arm Description

Oral synbiotic (food supplement) containing 8 probiotic Lactobacillus strains, the prebiotics inulin, fructooligosaccharides (FOS) and D-mannose.

Matching placebo

Outcomes

Primary Outcome Measures

Gestational age at delivery

Secondary Outcome Measures

Incidence of PTB, defined as GA at delivery < 37 weeks
Proportion of PTB in different categories
of patients that deliver < 28 weeks: extreme PTB of patients that deliver from 28 until 37 weeks: very PTB of patients that deliver from 32 until 37 weeks: moderate to late PTB
PPROM
Incidence
PPROM
Gestational age at PPROM
PPROM
Time to delivery
Composition of the vaginal microbiome
The vaginal microbiome will be assessed throughout pregnancy at 4 well-defined stages of pregnancy (9, 20, 30 weeks and at delivery) and at admission at the MIC unit for preterm labor, PPROM or cervical insufficiency.
Incidence of neonatal admissions
Duration of neonatal admissions
Incidence of maternal admissions
Duration of maternal admissions
Quality Of Life during pregnancy and during neonatal admission at a neonatal intensive care unit
Using EQ5D questionnaire (5 questions and scale from 1 to 100)
Neonatal outcome: infectious parameters
Sepsis (early, late and culture negative), number of episodes (min 72 hours) of antibiotic treatment, duration of antibiotic treatment in days
Neonatal outcome: bronchopulmonary dysplasia (BPD)
Proportion of each category (no, mild, moderate and severe)
Neonatal outcome: intraventricular haemorrhage
Incidence
Neonatal outcome: periventricular leukomalacia
Incidence
Neonatal outcome: respiratory support
Need for respiratory support (CPAP: continuous positive airways pressure, non-invasive positive pressure ventilation or mechanical endotracheal ventilation) and the duration of respiratory support in days. Use and administration of surfactant
Neonatal outcome: retinopathy
Incidence
Neonatal outcome: neonatal morbidity
Incidence
Neonatal outcome: birth weight

Full Information

First Posted
March 2, 2023
Last Updated
July 25, 2023
Sponsor
Ziekenhuis Oost-Limburg
search

1. Study Identification

Unique Protocol Identification Number
NCT05966649
Brief Title
Synbiotics in Patients at RIsk fOr Preterm Birth
Acronym
PRIORI
Official Title
Synbiotics in Patients at RIsk fOr Preterm Birth: a Multi-center Double-blind Randomized Placebo-controlled trIal
Study Type
Interventional

2. Study Status

Record Verification Date
June 2023
Overall Recruitment Status
Recruiting
Study Start Date
March 16, 2023 (Actual)
Primary Completion Date
December 2026 (Anticipated)
Study Completion Date
June 2027 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Ziekenhuis Oost-Limburg

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
Yes

5. Study Description

Brief Summary
Prematurity remains the main cause of death and serious health problems in new-borns. Besides the need for hospitalization and medical interventions in the first weeks or months of the new-borns' life, prematurity can cause long-lasting health problems (e.g. multiple hospital admissions, developmental delay, learning difficulties, motor delay, hearing or eye problems, ...). Moreover, prematurity places an enormous economic burden on the society. Aside from the medical problems and the financial cost, the emotional stress and psychological impact on the parents, siblings and other family members should not be underestimated. Previous preterm delivery (before 37 weeks of pregnancy) increases the risk for recurrent preterm delivery in a subsequent pregnancy. Therefore, these women should be considered as 'high risk' for preterm birth. Infections ascending from the vagina may be an important cause of preterm delivery in certain cases. Some women have an abnormal vaginal microbiome and are therefore at risk for infections and preterm birth. On the other hand, the vaginal flora is more stable and resistant to infections in healthy pregnant women who deliver at term (after 37 weeks of gestation). Synbiotics are a mixture containing probiotics and prebiotics. Probiotics are living bacteria with potential beneficial effects that can be used safely in pregnancy, while prebiotics are consumed by the bacteria. It is known that probiotics, when used for a long period of time, can maintain a healthy and stable vaginal flora that may protect against infections. In this study, pregnant patients with a history of preterm birth will be included in the first trimester of pregnancy to start with synbiotics or placebo. The investigators will examine the effect of synbiotics on the vaginal flora and on the pregnancy duration. The hypothesis is that synbiotics, when started early in the pregnancy, can change the disturbed vaginal flora into a stable micro-environment.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Preterm Spontaneous Labor With Preterm Delivery, Preterm Birth, Microbial Colonization
Keywords
Preterm birth, Vaginal microbiome, Probiotics, Synbiotics

7. Study Design

Primary Purpose
Other
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
ParticipantCare ProviderInvestigatorOutcomes Assessor
Allocation
Randomized
Enrollment
402 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Synbiotics
Arm Type
Experimental
Arm Description
Oral synbiotic (food supplement) containing 8 probiotic Lactobacillus strains, the prebiotics inulin, fructooligosaccharides (FOS) and D-mannose.
Arm Title
Placebo
Arm Type
Placebo Comparator
Arm Description
Matching placebo
Intervention Type
Other
Intervention Name(s)
Synbiotics
Intervention Description
Oral synbiotic (food supplement) containing 8 probiotic Lactobacillus strains, the prebiotics inulin, fructooligosaccharides (FOS) and D-mannose.
Intervention Type
Other
Intervention Name(s)
Placebo
Intervention Description
Matching placebo
Primary Outcome Measure Information:
Title
Gestational age at delivery
Time Frame
Through study completion - at delivery
Secondary Outcome Measure Information:
Title
Incidence of PTB, defined as GA at delivery < 37 weeks
Time Frame
Through study completion - at delivery
Title
Proportion of PTB in different categories
Description
of patients that deliver < 28 weeks: extreme PTB of patients that deliver from 28 until 37 weeks: very PTB of patients that deliver from 32 until 37 weeks: moderate to late PTB
Time Frame
Through study completion - at delivery
Title
PPROM
Description
Incidence
Time Frame
Up to 34 weeks from the date of randomization
Title
PPROM
Description
Gestational age at PPROM
Time Frame
Up to 34 weeks from the date of randomization
Title
PPROM
Description
Time to delivery
Time Frame
Up to 34 weeks from the date of randomization
Title
Composition of the vaginal microbiome
Description
The vaginal microbiome will be assessed throughout pregnancy at 4 well-defined stages of pregnancy (9, 20, 30 weeks and at delivery) and at admission at the MIC unit for preterm labor, PPROM or cervical insufficiency.
Time Frame
Assessed 3 times during the study period: at randomization, 11-13 weeks after randomization (at gestational age 19-21 weeks), and 21-23 weeks after randomization (29-31 weeks of gestation)
Title
Incidence of neonatal admissions
Time Frame
Neonatal admission at a neonatal intensive care unit (when the neonate is admitted at a neonatal intensive care unit within 7 days of delivery)
Title
Duration of neonatal admissions
Time Frame
Neonatal admission at a neonatal intensive care unit (when the neonate is admitted at a neonatal intensive care unit within 7 days of delivery)
Title
Incidence of maternal admissions
Time Frame
Up to 34 weeks from the date of randomization
Title
Duration of maternal admissions
Time Frame
Up to 34 weeks from the date of randomization
Title
Quality Of Life during pregnancy and during neonatal admission at a neonatal intensive care unit
Description
Using EQ5D questionnaire (5 questions and scale from 1 to 100)
Time Frame
Trough study completion, on avarage 1 year
Title
Neonatal outcome: infectious parameters
Description
Sepsis (early, late and culture negative), number of episodes (min 72 hours) of antibiotic treatment, duration of antibiotic treatment in days
Time Frame
During the admission at the neonatal intensive care unit (when the neonate is admitted at a neonatal intensive care unit within 7 days of delivery)
Title
Neonatal outcome: bronchopulmonary dysplasia (BPD)
Description
Proportion of each category (no, mild, moderate and severe)
Time Frame
During the admission at the neonatal intensive care unit (when the neonate is admitted at a neonatal intensive care unit within 7 days of delivery)
Title
Neonatal outcome: intraventricular haemorrhage
Description
Incidence
Time Frame
During the admission at the neonatal intensive care unit (when the neonate is admitted at a neonatal intensive care unit within 7 days of delivery)
Title
Neonatal outcome: periventricular leukomalacia
Description
Incidence
Time Frame
During the admission at the neonatal intensive care unit (when the neonate is admitted at a neonatal intensive care unit within 7 days of delivery)
Title
Neonatal outcome: respiratory support
Description
Need for respiratory support (CPAP: continuous positive airways pressure, non-invasive positive pressure ventilation or mechanical endotracheal ventilation) and the duration of respiratory support in days. Use and administration of surfactant
Time Frame
During the admission at the neonatal intensive care unit (when the neonate is admitted at a neonatal intensive care unit within 7 days of delivery)
Title
Neonatal outcome: retinopathy
Description
Incidence
Time Frame
During the admission at the neonatal intensive care unit (when the neonate is admitted at a neonatal intensive care unit within 7 days of delivery)
Title
Neonatal outcome: neonatal morbidity
Description
Incidence
Time Frame
During the admission at the neonatal intensive care unit (when the neonate is admitted at a neonatal intensive care unit within 7 days of delivery)
Title
Neonatal outcome: birth weight
Time Frame
After the neonate is born
Other Pre-specified Outcome Measures:
Title
Effect of antibiotics on the vaginal microbiome
Description
When the patient is admitted in case the pregnancy was complicated with PPROM
Time Frame
During pregnancy until 28 days after PPROM
Title
Effect on the gastrointestinal microbiome of the neonate in case of PPROM
Description
When the neonate is born after a pregnancy complicated with PPROM
Time Frame
Between 13 to 36 weeks from the date of randomization
Title
Placental microbiome in case of preterm birth
Description
In case the pregnancy was complicated with preterm birth (delivery before 37 weeks of gestation)
Time Frame
Between 13 to 36 weeks from the date of randomization

10. Eligibility

Sex
Female
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria: Signed written informed consent must be obtained before any study assessment is performed; 18 years of age or older; Singleton pregnancy; Pregnancy consultation between 8 and 10 weeks gestation. At least one of the following risk factors for spontaneous preterm birth: Prior spontaneous preterm birth, defined as delivery between 24 and 37 weeks following PPROM, preterm labor or cervical insufficiency PPROM ≤37 weeks in previous pregnancy but delivery ≥37 weeks Prior spontaneous second-trimester pregnancy loss, defined as PPROM, preterm labor or cervical insufficiency with birth between 14 and 24 weeks. Exclusion Criteria: Patients who are already using pro-, pre- or synbiotics Multiple pregnancy Need for primary (type 1) cerclage Inflammatory bowel disease Known congenital uterine anomaly History of LLETZ conization
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Caroline Van Holsbeke, PhD
Phone
003289327521
Email
Caroline.van.holsbeke@zol.be
First Name & Middle Initial & Last Name or Official Title & Degree
Katrien Nulens, MD
Phone
003289327521
Email
Katrien_Nulens@hotmail.com
Facility Information:
Facility Name
Ziekenhuis Oost-Limburg
City
Genk
State/Province
Limburg
ZIP/Postal Code
3600
Country
Belgium
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Els Papy, MSc
Phone
0032 89 32 75 30
Email
els.papy@zol.be
First Name & Middle Initial & Last Name & Degree
Myrthe Hoeven, MSc
Phone
0032 89 32 75 31
Email
myrthe.hoeven@zol.be
First Name & Middle Initial & Last Name & Degree
Caroline Van Holsbeke, PhD
Facility Name
Universitaire Ziekenhuizen Leuven
City
Leuven
State/Province
Limburg
ZIP/Postal Code
3000
Country
Belgium
Individual Site Status
Not yet recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Ann-Julie Trippas
Phone
0032 16 34 64 51
Email
ann-julie.trippas@uzleuven.be
First Name & Middle Initial & Last Name & Degree
Roland Devlieger, PhD
Facility Name
UZ Gent
City
Gent
State/Province
Oost-Vlaanderen
ZIP/Postal Code
9000
Country
Belgium
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Astrid Luypaert, PhD
Phone
0032 9 332 07 58
Email
gynobs.studies@uzgent.be
First Name & Middle Initial & Last Name & Degree
Isabelle Dehaene, PhD
Facility Name
AZ Sint-Jan
City
Brugge
State/Province
West-Vlaanderen
ZIP/Postal Code
8300
Country
Belgium
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Premilla Rousseau
Email
Premila.Rousseau@azsintjan.be
First Name & Middle Initial & Last Name & Degree
Joachim Van Keirsbilck
Facility Name
AZ Sint-Lucas
City
Brugge
State/Province
West-Vlaanderen
ZIP/Postal Code
8310
Country
Belgium
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Veerle De Prest
Phone
0032 50 36 51 04
Email
studies.gynaeco@stlucas.be
First Name & Middle Initial & Last Name & Degree
Caroline Van Holsbeke, PhD
Facility Name
CHR Citadelle
City
Liège
ZIP/Postal Code
4000
Country
Belgium
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Marie Timmermans
Phone
0032 4 321 75 57
Email
marie.timmermans@chuliege.be
First Name & Middle Initial & Last Name & Degree
Véronique Masson

12. IPD Sharing Statement

Plan to Share IPD
Undecided

Learn more about this trial

Synbiotics in Patients at RIsk fOr Preterm Birth

We'll reach out to this number within 24 hrs